Intervention(s) and comparator(s)	Participants included in analysis [N]	Deaths [N]	Deaths [%]	Participants with adverse events [N]	Participants with adverse events [%]	Participants with severe/serious adverse events [N]	Participants with severe/serious adverse events [%]
Hero 2005	I: etrozole	16	0	0	0	0	0	0
	C: placebo	15	0	0	1	7	1	7
Mauras 2008	I: anastrozole + GH	26	0	0	‐	‐	4	15
	C: placebo + GH	26	0	0	‐	‐	0	0
Salehpour 2010	I1: letrozole	31	0	0	0	0	0	0
	I2: oxandrolone	30	0	0	0	0	0	0
	C: placebo	30	0	0	0	0	0	0
Wickman 2001	I: letrozole + testosterone	11	0	0	‐	‐	‐	‐
	C1: placebo + testosterone	12	0	0	‐	‐	‐	‐
	C2: no treatment	10	0	0	‐	‐	‐	‐
"‐" denotes not reported GH: growth hormone; N: number of participants